Plant Name: Ostericum grosseserratum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; OPRK1; | |
| FFAR1; FFAR4; | |
| GAA; | |
| GLA; FAAH; TDP1; TERT; HPGD; GFER; HSD17B10; ALOX15; ALDH1A1; USP2; BRCA1; POLB; | |
| CHRNA7; | |
| ATM; PTK2B; | |
| CA2; CA12; CA1; CA9; CA3; CA5A; CA14; CA5B; CA4; CA6; CA7; | |
| PPARA; PPARD; PPARG; | |
| ESR2; | |
| CASP1; CASP7; | |
| TLR2; | |
| AHR; TP53; HIF1A; | |
| KMT2A; | |
| SLC22A8; SLC22A6; | |
| ABCC1; | |
| HTT; NPC1; FABP3; FABP5; SERPINA6; FABP2; FABP4; LMNA; MAPT; HBB; TTR; RAB9A; | |
| SMN1;SMN2; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2B6 | Cytochrome P450 2B6 | P20813 | CHEMBL4729 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nicotinic acetylcholine receptor | CHRNA7 | Neuronal acetylcholine receptor protein alpha-7 subunit | P36544 | CHEMBL2492 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRK1 | Kappa opioid receptor | P41145 | CHEMBL237 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | ATM | Serine-protein kinase ATM | Q13315 | CHEMBL3797 |
| Protein Kinase | PTK2B | Protein tyrosine kinase 2 beta | Q14289 | CHEMBL5469 |
| SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.785E-12 | 2.757E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.091E-12 | 7.070E-09 | ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB, XDH |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.906E-11 | 4.653E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.157E-10 | 6.460E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.617E-10 | 1.750E-07 | CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.572E-10 | 3.111E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 9.651E-10 | 4.471E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NPC1, PPARD, SERPINA6 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.068E-09 | 8.337E-07 | BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, KMT2A, PPARA, PPARD, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 3.254E-09 | 1.265E-06 | BRCA1, CA2, CA9, CASP1, CASP7, CYP1A1, CYP1A2, CYP1B1, HPGD, NPC1, OPRK1, PPARG, PTK2B, SLC22A6, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 1.392E-08 | 4.663E-06 | ALOX15, CA2, CYP1A1, CYP1A2, FABP4, HIF1A, KMT2A, NPC1, PTK2B, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.491E-08 | 4.847E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.806E-08 | 1.976E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.665E-07 | 4.265E-05 | CYP1A2, CYP2C9, CYP3A4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.870E-07 | 7.101E-05 | ABCC1, CA2, CA4, CA9, HPGD, SLC22A6, SLC22A8, TSHR |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 7.874E-07 | 1.786E-04 | AHR, ESR2, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 8.035E-07 | 1.804E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.415E-06 | 3.082E-04 | CYP1A1, CYP1A2, PPARG, PTK2B |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.680E-06 | 3.552E-04 | FABP2, FABP3, FABP4, FABP5 |
| CC | GO:0043226; organelle | GO:0043227; membrane-bounded organelle | 2.138E-06 | 4.310E-04 | ABCC1, AHR, ALDH1A1, ATM, BRCA1, CA1, CA2, CA4, CA5A, CA5B, CA6, CASP1, CASP7, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, ESR2, FABP3, FABP4, FABP5, FFAR4, GAA, GFER, GLA, HBB, HIF1A, HPGD, HSD17B10, HTT, KMT2A, LMNA, MAPT, NPC1, POLB, PPARA, PPARD, PPARG, PTK2B, RAB9A, SERPINA6, SLC22A6, SLC22A8, SMN1, SMN2, TDP1, TERT, TLR2, TP53, TTR, XDH |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 3.328E-06 | 6.588E-04 | CA3, HPGD, OPRK1, POLB, PTK2B, TP53 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 3.754E-06 | 7.299E-04 | ALOX15, BRCA1, CASP1, CASP7, CYP1A1, CYP1B1, FABP4, FFAR4, HIF1A, NPC1, OPRK1, PPARD, PPARG, PTK2B, TP53, TSHR |
| CC | GO:0044464; cell part | GO:0044444; cytoplasmic part | 4.136E-06 | 7.831E-04 | AHR, ALDH1A1, ALOX15, ATM, BRCA1, CA1, CA2, CA3, CA4, CA5A, CA5B, CA7, CASP1, CASP7, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, ESR2, FAAH, FABP2, FABP3, FABP4, FABP5, FFAR4, GAA, GFER, GLA, HBB, HIF1A, HPGD, HSD17B10, HTT, KMT2A, LMNA, MAPT, NPC1, PPARG, PTK2B, RAB9A, SMN1, SMN2, TERT, TLR2, TP53, TTR, USP2, XDH |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 5.673E-06 | 1.029E-03 | AHR, ATM, CHRNA7, GLA, HIF1A, HPGD, KMT2A, MAPT, PPARD, PPARG, SLC22A6, TERT, TLR2, TP53, TTR, XDH |
| BP | GO:0009987; cellular process | GO:0090399; replicative senescence | 8.974E-06 | 1.551E-03 | ATM, TERT, TP53 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 9.130E-06 | 1.553E-03 | CASP1, CHRNA7, ESR2, GLA, HPGD, HTT, KMT2A, MAPT, PPARG, RAB9A, SLC22A6, SMN1, SMN2, TERT, TP53, TTR, USP2, XDH |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 1.030E-05 | 1.725E-03 | CASP1, CASP7, MAPT, PPARG, XDH |
| BP | GO:0065007; biological regulation | GO:0065009; regulation of molecular function | 1.380E-05 | 2.226E-03 | ALDH1A1, ATM, CASP1, CASP7, CHRNA7, CYP1B1, CYP2D6, ESR2, FABP4, FFAR1, GFER, GLA, HIF1A, HTT, KMT2A, MAPT, PPARA, PPARG, PTK2B, RAB9A, SERPINA6, TERT, TLR2, TP53, TSHR, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.624E-05 | 2.525E-03 | HBB, MAPT, PTK2B, TP53, XDH |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.696E-05 | 2.611E-03 | BRCA1, CHRNA7, CYP1B1, HIF1A, PTK2B, TERT |
| BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 1.713E-05 | 2.611E-03 | CASP7, OPRK1, PPARG, PTK2B, TP53 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 2.739E-05 | 3.775E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.739E-05 | 3.775E-03 | CYP2B6, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 3.143E-05 | 4.225E-03 | ALOX15, ATM, CASP1, CHRNA7, CYP1B1, FFAR4, HTT, OPRK1, PPARD, PTK2B, TLR2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.271E-05 | 4.353E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 3.279E-05 | 4.353E-03 | HIF1A, PTK2B, TERT |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.489E-05 | 4.576E-03 | AHR, BRCA1, ESR2, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.655E-05 | 4.709E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.655E-05 | 4.709E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.655E-05 | 4.709E-03 | CYP1A1, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 4.184E-05 | 5.297E-03 | AHR, KMT2A, PPARA, USP2 |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 4.557E-05 | 5.638E-03 | AHR, PPARA, TERT |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 5.525E-05 | 6.574E-03 | ESR2, PPARA, PPARD, PPARG |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 5.635E-05 | 6.668E-03 | ATM, CA2, CYP1A1, CYP1A2, GFER, HIF1A, HPGD, HTT, KMT2A, POLB, PPARA, PPARD, PPARG, USP2 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 6.125E-05 | 7.210E-03 | HIF1A, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.026E-05 | 8.095E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.294E-05 | 8.315E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 9.079E-05 | 9.919E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 9.110E-05 | 9.919E-03 | FABP3, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.933E-25 | 1.292E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.511E-20 | 2.734E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.462E-17 | 1.257E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.841E-14 | 6.433E-11 | CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.650E-24 | 4.563E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.219E-09 | 2.175E-07 | CYP2C9; CYP2B6; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.493E-09 | 2.175E-07 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.189E-08 | 3.715E-07 | CYP2C9; CHRNA7; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.700E-08 | 1.812E-06 | CYP2C9; CYP2B6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.249E-07 | 2.231E-06 | CYP2C9; CYP2B6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.361E-08 | 1.090E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.876E-05 | 8.162E-04 | CYP2C9; CYP2B6; ALOX15; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.515E-05 | 7.055E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.681E-04 | 3.834E-03 | HPGD; KMT2A; ATM; PPARG; TP53 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.760E-04 | 5.538E-03 | CYP2C9; CYP2D6; ALOX15; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.394E-04 | 3.834E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.324E-03 | 1.103E-02 | CASP7; LMNA; ATM; TP53 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 8.690E-04 | 7.759E-03 | CASP7; CASP1; TLR2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.906E-03 | 2.018E-02 | CYP2C9; CYP2B6; GAA; CYP1A2; ALOX15; ALDH1A1; CYP1A1; CYP2C19; CYP3A4; HSD17B10; XDH |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.393E-03 | 2.232E-02 | ABCC1; CYP1B1; ATM; BRCA1; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.821E-03 | 1.423E-02 | CA2; SLC22A8; CYP3A4 |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 8.507E-03 | 4.833E-02 | NPC1; GAA; GLA |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.358E-03 | 2.724E-02 | PPARG; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.659E-03 | 2.773E-02 | GAA; GLA |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.752E-03 | 2.018E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.132E-04 | 1.414E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRNA7; CHRNA7; CHRNA7 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRK1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | OPRK1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRNA7 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | OPRK1; MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRNA7; CHRNA7; MAPT; PPARG; PPARG |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; TLR2; HIF1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH; CHRNA7 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | CHRNA7 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | ABCC1; ABCC1; XDH; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SERPINA6; FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CA1; CA9; TLR2; HIF1A |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | CHRNA7 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| NA: NA | Obstructive airway diseases | NA | SERPINA6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRK1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | HIV infections | NA | AHR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRNA7 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | PTK2B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SERPINA6; CHRNA7 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | CHRNA7 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| NA: NA | Edema | NA | CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; CHRNA7; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | OPRK1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRNA7; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | OPRK1; PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ATM |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | OPRK1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | OPRK1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRK1; FAAH |